Immunotherapy of melanoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Melanoma treatment has been revolutionized by immunotherapy, particularly immune checkpoint inhibitors.
• Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) inhibitors have shown significant efficacy.
• These therapies offer improved tolerability and durable responses compared to traditional cytokine-based treatments.

Purpose of the Study:

• To review the advancements in immunotherapy for advanced melanoma.
• To discuss the efficacy and side effect profiles of CTLA-4 and PD-1 inhibitors.
• To highlight emerging challenges and future research directions in melanoma immunotherapy.

Main Methods:

• Review of clinical trial data and published literature on immune checkpoint inhibitors in melanoma.
• Analysis of response rates, overall survival, progression-free survival, and adverse events.
• Discussion of combination strategies and novel therapeutic approaches.

Main Results:

• Ipilimumab (anti-CTLA-4) was the first to demonstrate improved overall survival in melanoma.
• Pembrolizumab and Nivolumab (anti-PD-1) show improved single-agent activity and tolerability versus ipilimumab.
• Combination therapy (nivolumab and ipilimumab) yields higher response rates but increases autoimmune side effects.

Conclusions:

• Immune checkpoint inhibitors represent a major breakthrough in advanced melanoma treatment.
• Managing autoimmune side effects and understanding non-standard response kinetics are crucial.
• Future research focuses on novel targets, combination strategies, and predictive biomarkers for personalized treatment.